Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winer

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
JCO Oncology Advances|February 5, 2025
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023Caroline Schenkel, Laura A Levit, Kelsey Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2016
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast CancerIngrid A Mayer, Vandana G Abramson, Luigi Formisano, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerIngrid A Mayer, Vandana G Abramson, Steven J Isakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Cancer|March 23, 2023
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohortsAnna Weiss, Olga Martínez-Sáez, Adrienne G Waks, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with invasive carcinoma of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.
Cancer Cell|January 9, 2026
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapyAndrea H Bild, Michelle C Sangar, Jasmine A McQuerry, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
JCO Oncology Advances|February 5, 2025
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023Caroline Schenkel, Laura A Levit, Kelsey Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2016
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast CancerIngrid A Mayer, Vandana G Abramson, Luigi Formisano, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerIngrid A Mayer, Vandana G Abramson, Steven J Isakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Cancer|March 23, 2023
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohortsAnna Weiss, Olga Martínez-Sáez, Adrienne G Waks, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with invasive carcinoma of the breastSusan C Lester, Shikha Bose, Yunn-Yi Chen, et al.
Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.
Cancer Cell|January 9, 2026
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapyAndrea H Bild, Michelle C Sangar, Jasmine A McQuerry, et al.
Pageof 11